During the 124th annual meeting of the American Roentgen Ray Society (ARRS), several clinical issues related to theranostics treatments were discussed. Theranostics treatments are being used with increasing frequency for neuroendocrine tumors and prostate cancer. Three clinical issues were highlighted: sialoadenitis and xerostomia as common but not serious side effects of prostate-specific membrane antigen (PSMA) treatments, carcinoid crisis as a serious but rare event with DOTATATE therapies, and extravasations as a potential side effect of intravenous radiopharmaceutical therapies. Erica Cohen Major, a nuclear medicine specialist, emphasized the importance of recognizing and managing these issues during treatment. Extravasations, where injectate leaks into subcutaneous tissues, can cause radiation injury and have varying effects depending on the amount of radiation exposure. Major shared a case study of successful management of extravasation in a patient who received lutetium DOTATOC. Carcinoid crisis, a sudden release of vasoactive substances into the bloodstream, can occur with DOTATATE treatments and requires close monitoring and intervention. Sialoadenitis and xerostomia, which cause trouble eating and dry mouth, are common side effects of PSMA treatments and can be identified by listening to patient symptoms. Attention to these clinical issues is crucial for the safe and effective use of theranostics treatments.
Wed, 08 May 2024 07:01:09 GMT | AuntMinnie